TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 6963097
Drug: Activated charcoal
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Activated charcoal administration during maintenance therapy with digitoxin
Study: 6963097
Drug: Fibre administration
Normalized name: Fiore
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fibre administration
Study: 26474237
Drug: Low-dose rifaximin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose rifaximin (400mg every 12 hours for 2 weeks)
Study: 26474237
Drug: High-dose rifaximin
Normalized name: Rifaximin
DrugBank: Rifaximin (DB01220)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High-dose rifaximin (600mg every 12 hours for 2 weeks)
Study: 26474237
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no rifaximin treatment)
Study: 9218083
Drug: Zamifenacin 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zamifenacin 40 mg
Study: 9218083
Drug: Zamifenacin 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zamifenacin 10 mg
Study: 7752825
Drug: 500 mcg
Normalized name: Nplate 500 MCG Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mcg of selenium (as sodium selenite) followed by 100 mg coenzyme Q10 (Bio‐Quinone) and 100 mcg selenium (Bio‐Selenium in the form of 1‐seleno‐methionine) for one year
Study: 7752825
Drug: Matching placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo preparations
Study: 3054778
Drug: Ceftriaxone, 80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone, 80 to 100 mg/kg/day for 4 days
Study: 31473324
Drug: Normothermia and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normothermia and early treatment of fever (≥37.8°C)
Study: 28343218
Drug: L-carnitine supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-carnitine supplementation (50 mg/kg)
Study: 26604728
Drug: Mud Bath
Normalized name: colloidal oatmeal
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mud Bath Therapy (MBT), n=22
Study: 18788410
Drug: Erythropoietin stimulating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythropoietin stimulating agents (ESAs) treatment targeting higher hemoglobin levels (near normal level)
Study: 18788410
Drug: Erythropoietin stimulating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythropoietin stimulating agents (ESAs) treatment targeting lower hemoglobin levels (sub-normal level)
Study: 9186459
Drug: Octreotide (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Octreotide (200 micrograms intravenous)
Study: 1586104
Drug: Zidovudine, 1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zidovudine, 1200 mg/d
Study: 9229416
Drug: Multimodality therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multimodality therapy
Study: 29738282
Drug: Caffeine (CAF)
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine (CAF) 6 mg/kg BM
Study: 22293631
Drug: Genistein 300
Normalized name: calcium carb,citrate/vitamin D3/mineral comb no.34/genistein 300 mg-200 unit-13.5 mg ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Genistein 300 mg/d
Study: 22293631
Drug: Genistein 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Genistein 600 mg/d
Study: 17235043
Drug: Pertuzumab 420
Normalized name: pertuzumab 420 MG in 14 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pertuzumab 420 mg (loading dose of 840 mg)
Study: 17235043
Drug: Pertuzumab 1,050
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pertuzumab 1,050 mg
Study: 401699
Drug: Fenoprofen (2,400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenoprofen (2,400 mg/day)
Study: 401699
Drug: Aspirin (3,900
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (3,900 mg/day)
Study: 401699
Drug: Gold induction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gold induction therapy
Study: 17827352
Drug: Intermittent preventive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent preventive anti-malarial treatment (artesunate and sulfadoxine-pyrimethamine)
Study: 15471830
Drug: Radionuclide therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radionuclide therapy with 131I-MIBG (3.7-7.4 GBq, n = 5) or 111In-pentetreotide (7 GBq, n = 15) administered 3 times monthly
Study: 3149935
Drug: Nitroglycerin (N)
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitroglycerin (N) + Heparin (H)
Study: 18327721
Drug: Flu vaccine
Normalized name: flu vaccine 2012 (18-64yrs)/PF 27 mcg/0.1 mL INTRADERM SYRINGE (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flu vaccine
Study: 15818640
Drug: Advice and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Advice and exercise plus manual therapy
Study: 10487668
Drug: Alendronate (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alendronate (10 mg/day) plus HRT
Study: 6620717
Drug: Topical phenylephrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical phenylephrine (20 microliters of phenylephrine HCL 10%)
Study: 31467049
Drug: Xuebijing Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xuebijing Injection (XBJ), every 12 hours for 5 days
Study: 31467049
Drug: Xuebijing Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xuebijing Injection (XBJ)
Study: 27036408
Drug: Personalized normative
Normalized name: K Norm
Approvals — FDA: no, EMA: no, PMDA: no
Description: Personalized normative feedback (PNF) intervention, delivered online, single module, details on dosage and duration not specified.
Study: 24699050
Drug: Aspirin 75
Normalized name: aspirin 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 75 to 150 mg/d plus clopidogrel 75 mg/d (A+C)
Study: 24699050
Drug: Warfarin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin therapy (international normalized ratio 2‐3)
Study: 24699050
Drug: Aspirin plus
Normalized name: Aspirin Plus Antacid Extra Strength
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin plus clopidogrel (A+C)
Study: 22251528
Drug: 3-week method
Normalized name: etonogestrel
DrugBank: Etonogestrel (DB00294)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3-week method of S-1 administration
Study: 22251528
Drug: 4-week method
Normalized name: milnacipran
DrugBank: Milnacipran (DB04896)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4-week method of S-1 administration
Study: 17116123
Drug: Oral rabeprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral rabeprazole 20 mg
Study: 9798809
Drug: Intravenous pantoprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous pantoprazole 40 mg
Study: 14605051
Drug: Antibiotics administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics administered within 4 hours (group 1)
Study: 14605051
Drug: Antibiotics administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics administered between 4 to 8 hours (group 2)
Study: 14605051
Drug: Antibiotics administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics administered after 8 hours (group 3)
Study: 10761530
Drug: Glycosylated G-CSF
Normalized name: Glycosylated recombinant G-CSF
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycosylated G-CSF (lenograstim, 2 micrograms/kg)
Study: 10761530
Drug: Mutated G-CSF
Normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mutated G-CSF (nartograstim, 1 microgram/kg)
Study: 1579299
Drug: 5 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 g of 2% clindamycin vaginal cream daily for 7 days
Study: 1579299
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg metronidazole oral tablets twice a day for 7 days
Study: 6436861
Drug: Vincamine (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vincamine (4 X 20 mg/day)
Study: 6436861
Drug: Bromvincamine (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromvincamine (4 X 20 mg/day)
Study: 17490965
Drug: Intravenous trace
Normalized name: Trace metal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous trace element (TE) supplementation (copper, selenium, zinc) for 14-21 days
Study: 11782615
Drug: High-dose interferon
Normalized name: interferon-beta
DrugBank: Human interferon beta (DB14999)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose interferon alfa-2b and ribavirin (5 MU/d for 4 weeks, 5 MU three times weekly for 8 weeks, then 3 MU three times weekly for 36 weeks)
Study: 11782615
Drug: Standard-dose interferon
Normalized name: INTERFERON
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose interferon alfa-2b and ribavirin (for 48 weeks)
Study: 10524468
Drug: Intrathecal morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal morphine and bupivacaine
Study: 1952438
Drug: Ibuprofen (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (800 mg given rectally every 4 h for three doses)
Study: 7037791
Drug: Sodium nitroprusside
Normalized name: Sodium Nitroprusside
DrugBank: Nitroprusside (DB00325)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Sodium nitroprusside (constant, variable dose infusion)
Study: 27930762
Drug: Standard-fractionation RT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-fractionation RT (70 Gy/35 over 7 weeks) plus cisplatin at 100 mg/m2 intravenous for 3 doses (arm A)
Study: 27930762
Drug: Accelerated-fractionation RT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Accelerated-fractionation RT (70 Gy/35 over 6 weeks) plus panitumumab at 9 mg/kg intravenous for 3 doses (arm B)
Study: 26446978
Drug: RSA-BF training
Normalized name: BF-844
DrugBank: BF-844 (DB17801)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RSA-BF training (5 weekly 45 min sessions)
Study: 26446978
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (daily stress diary once a week)
Study: 25123549
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg ASA daily
Study: 21740452
Drug: Standard triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard triple therapy plus vitamins C and E (lansoprazole 30 mg BID, amoxicillin 1000 mg BID, clarithromycin 500 mg BID for 14 days, plus vitamin C 500 mg BID and vitamin E 200 IU BID for 30 days)
Study: 21740452
Drug: Standard triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard triple therapy (lansoprazole 30 mg BID, amoxicillin 1000 mg BID, clarithromycin 500 mg BID for 14 days)
Study: 17259945
Drug: Pioglitazone (45
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone (45 mg/day for 4 months)
Study: 11994827
Drug: Transdermal Therapeutic
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal Therapeutic System (TTS) fentanyl with intramuscular Demerol
Study: 11994827
Drug: Placebo system
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo system with intramuscular Demerol
Study: 7516014
Drug: Perindopril (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perindopril (4 mg, single morning dose for 6 weeks)
Study: 4911757
Drug: Quinidine bisulphate
Normalized name: quinidine bisulfate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinidine bisulphate 1.5 g per day in two 12-hourly doses
Study: 31184266
Drug: Music therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Music therapy (listening to music through binaural headphones during pre-, intra-, and postprocedural periods)
Study: 25919976
Drug: Group A
Normalized name: Blood group A IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A (IBD patients on no immunosuppressive therapy)
Study: 25919976
Drug: Group B
Normalized name: Blood group B IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B (IBD patients on tumor necrosis factor agents or immunomodulators)
Study: 23918750
Drug: Angiotensin-(1-7) infusion
Normalized name: Angiotensin (1-7)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angiotensin-(1-7) infusion (3 incremental doses: 0.27, 0.9, and 2.7 ng/kg per minute)
Study: 23918750
Drug: Angiotensin-(1-7) infusion
Normalized name: Angiotensin (1-7)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angiotensin-(1-7) infusion with low sodium intake and/or angiotensin II co-infusion (0.3 ng/kg per minute)
Study: 25208127
Drug: Angiotensin-(1-7) infusion
Normalized name: Angiotensin (1-7)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angiotensin-(1-7) infusion
Study: 22164500
Drug: Compound purple
Normalized name: BENZOIN COMPOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compound purple granules (Control)
Study: 19329178
Drug: Relaxin (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Relaxin (all doses)
Study: 17082899
Drug: Subunit virus
Normalized name: covid-19, protein subunit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subunit virus vaccine adjuvanted with MF59
Study: 10485352
Drug: Split virus
Normalized name: INFLUENZA SPLIT VIRUS '95-'96 VIL 5ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Split virus vaccine
Study: 15383481
Drug: Long-term oral
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term oral anticoagulant (OAC) therapy (target INR 2.5; range 2.0 to 3.0) for patients with rheumatic mitral valve disease and AF or history of systemic embolism.
Study: 15383481
Drug: Adding aspirin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adding aspirin, 75 to 100 mg/d for patients with rheumatic mitral valve disease with AF or history of systemic embolism who suffer systemic embolism while receiving OACs at a therapeutic INR.
Study: 15383481
Drug: Adding dipyridamole,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adding dipyridamole, 400 mg/d, or clopidogrel for patients unable to take aspirin.
Study: 15383481
Drug: Long-term aspirin
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term aspirin therapy, 50 to 162 mg/d for patients with MVP and documented but unexplained TIAs.
Study: 15383481
Drug: Vitamin K
Normalized name: Vitamin K
DrugBank: Phylloquinone (DB01022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin K antagonists for all patients with mechanical prosthetic heart valves.
Study: 15383481
Drug: Target INR
Normalized name: Inrebic
DrugBank: Fedratinib (DB12500)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Target INR of 3.0 (range 2.5 to 3.5) in combination with aspirin, 75 to 100 mg/d for patients with caged ball or caged disk valves.
Study: 15383481
Drug: Vitamin K
Normalized name: Vitamin K
DrugBank: Phylloquinone (DB01022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin K antagonists with a target INR of 2.5 (range 2.0 to 3.0) for the first 3 months after valve insertion in the mitral position for patients with bioprosthetic valves.
Study: 15383481
Drug: Long-term (>
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-term (> 3 months) therapy with aspirin, 75 to 100 mg/d for patients with bioprosthetic valves who are in sinus rhythm and do not have AF.
Study: 15383481
Drug: No antithrombotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antithrombotic therapy for patients with MVP without history of systemic embolism, unexplained TIAs, or AF.
Study: 10522839
Drug: Metformin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin plus repaglinide (MET/REP)
Study: 10522839
Drug: Metformin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin plus placebo (MET)
Study: 7760966
Drug: Simvastatin monotherapy
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simvastatin monotherapy (20 to 80 mg/day)
Study: 7760966
Drug: Simvastatin in
Normalized name: Product containing simvastatin in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin in combination with other lipid-lowering agents
Study: 7760966
Drug: Simvastatin (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin (both monotherapy and combination therapy)
Study: 31551222
Drug: High-dose ambroxol
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose ambroxol
Study: 31551222
Drug: Small-dose ambroxol
Normalized name: ambroxol
DrugBank: Ambroxol (DB06742)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Small-dose ambroxol (Control)
Study: 28620884
Drug: Indirect response
Normalized name: Besponsa
DrugBank: Inotuzumab ozogamicin (DB05889)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Indirect response model with linear drug effect
Study: 24969152
Drug: Augmented Standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Augmented Standard Care (ASC; lower dose)
Study: 24969152
Drug: Resource Nurse
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resource Nurse Care (RNC; medium dose)
Study: 24969152
Drug: Transitional Care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transitional Care Model (TCM; higher dose)
Study: 18066659
Drug: Self-guided reading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-guided reading plus nicotine patch (n = 18)
Study: 18066659
Drug: Motivational interviewing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Motivational interviewing plus nicotine patch (n = 22)
Study: 18066659
Drug: Nicotine patch
Normalized name: Nicotine Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine patch compliance
Study: 15168925
Drug: 0.06 mg
Normalized name: urea 0.06 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.06 mg x Kg(‐1) of rocuronium
Study: 9613753
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin injections (25-50 U per site, mean total dose 210 U, range 150-300 U)
Study: 2680315
Drug: Single-dose therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose therapy with sulfamethizole
Study: 2680315
Drug: Conventional six-day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional six-day therapy with sulfamethizole
Study: 31669050
Drug: Dexmedetomidine (D
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (D group) - loading dose of 0.5 μg/kg for 10 min, maintained at 0.5 μg/kg/h until liver resection
Study: 31669050
Drug: Control (C
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (C group) - 0.9% sodium chloride administered in the same volume and infusion rate as D group
Study: 21067717
Drug: rFSH +
Normalized name: rFSH-alpha
DrugBank: Follitropin (DB00066)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: rFSH + rLH administration
Study: 21067717
Drug: rFSH administration
Normalized name: rFSH-alpha
DrugBank: Follitropin (DB00066)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: rFSH administration
Study: 18181381
Drug: Remifentanil infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil infusion (RI)
Study: 18181381
Drug: Remifentanil infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil infusion with paracervical block (RI + PCB)
Study: 14985684
Drug: Lactulose (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactulose (5 g b.i.d. for 6 weeks)
Study: 14985684
Drug: Placebo (sucrose,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (sucrose, 5 g b.i.d. for 6 weeks)
Study: 8089468
Drug: Multiple drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple drug regimen including a macrolide for treatment of DMAC
Study: 24111816
Drug: Diluted bleach
Normalized name: beach strawberry extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diluted bleach baths (soaked for 10 min, twice a week for 2 months)
Study: 11893345
Drug: Fluoxetine (10-80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (10-80 mg/d)
Study: 10739391
Drug: Inhaled nitric
Normalized name: nitric oxide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled nitric oxide (NO) at 10 ppm
Study: 2104988
Drug: High-dose TRH
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose TRH (0.5 mg/kg) administered intravenously (IV)
Study: 2104988
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered intravenously (IV)
Study: 335498
Drug: 100-400 mg
Normalized name: sofosbuvir 400 MG / velpatasvir 100 MG [Epclusa]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100-400 mg spironolactone
Study: 335498
Drug: 100-200 mg
Normalized name: immunoglobulin G
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100-200 mg spironolactone
Study: 335498
Drug: spironolactone with
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: spironolactone with other antihypertensive regimens
Study: 29427176
Drug: Open-label subcutaneous
Normalized name: Ga-68-Labeled PSMA-11
DrugBank: Gallium Ga-68 gozetotide (DB16019)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open-label subcutaneous golimumab 50 mg every 4 weeks (q4w) through week 12, continued for responders through week 52.
Study: 29427176
Drug: Open-label subcutaneous
Normalized name: Ga-68-Labeled PSMA-11
DrugBank: Gallium Ga-68 gozetotide (DB16019)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open-label subcutaneous golimumab 50 mg q4w through week 44 (N = 75).
Study: 29427176
Drug: Double-blind subcutaneous
Normalized name: Io-Blend
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double-blind subcutaneous golimumab 50 mg q4w or intravenous golimumab 2 mg/kg (weeks 16, 20, every 8 weeks [q8w]) for nonresponders.
Study: 29427176
Drug: Previous adalimumab/etanercept
Approvals — FDA: no, EMA: no, PMDA: no
Description: Previous adalimumab/etanercept treatment.
Study: 21072973
Drug: Treatment FP
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment FP (fentanyl 0.02 mg kg(‐1) and propofol 12.0 mg kg(‐1) hour(‐1))
Study: 21072973
Drug: Treatment MP
Normalized name: 6 MP
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment MP (midazolam 0.3 mg kg(‐1) and propofol 12.0 mg kg(‐1) hour(‐1))
Study: 8583673
Drug: Midazolam syrup
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Midazolam syrup
Study: 11587494
Drug: Naratriptan 5
Normalized name: naratriptan 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naratriptan 5 mg
Study: 10972633
Drug: Naratriptan 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naratriptan 7.5 mg
Study: 11587494
Drug: Naratriptan 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naratriptan 10 mg
Study: 10972633
Drug: Naratriptan (any
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naratriptan (any dose)
Study: 9563208
Drug: Sumatriptan (any
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sumatriptan (any dose)
Study: 8761583
Drug: Sulfadoxine-pyrimethamine (S-P)
Normalized name: pyrimethamine / sulfadoxine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulfadoxine-pyrimethamine (S-P) given as a single dose of 0.8-1.4 mg pyrimethamine/kg body weight
Study: 8761583
Drug: Weekly dapsone-pyrimethamine
Normalized name: dapsone / pyrimethamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly dapsone-pyrimethamine prophylactic intervention
Study: 1423200
Drug: Concurrent 5‐fluorouracil,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent 5‐fluorouracil, cisplatin, and radiation therapy